A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
News|Articles|July 23, 2026
What Does It Take to Deliver CAR T-Cell Therapy in the Community?
Fact checked by: Justin Mancini
Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.
Advertisement
Advertisement
As chimeric antigen receptor (CAR) T-cell therapy expands beyond large academic medical centers, community oncology practices are increasingly evaluating whether they have the personnel, infrastructure, and operational capabilities required to deliver treatment safely in the outpatient setting.
Related to this article
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Advertisement
Advertisement